ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

PubWeight™: 12.32‹?› | Rank: Top 0.1% | All-Time Top 10000

🔗 View Article (PMID 18799522)

Published in Eur Heart J on September 17, 2008

Authors

Kenneth Dickstein1, Alain Cohen-Solal, Gerasimos Filippatos, John J V McMurray, Piotr Ponikowski, Philip Alexander Poole-Wilson, Anna Strömberg, Dirk J van Veldhuisen, Dan Atar, Arno W Hoes, Andre Keren, Alexandre Mebazaa, Markku Nieminen, Silvia Giuliana Priori, Karl Swedberg, ESC Committee for Practice Guidelines (CPG)

Author Affiliations

1: University of Bergen, Cardiology Division, Stavanger University Hospital, Norway. kenneth.dickstein@med.uib.no

Associated clinical trials:

A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation (RESHAPE-HF) | NCT01772108

Renal Denervation in Patients With Heart Failure and Severe Left Ventricular Dysfunction. | NCT01870310

Comparison of Cardiac Rehabilitation Benefits Between Coronary and Non-coronary Patients Through a 24 Months Follow-up After Myocardial Infarction: the "INCARD" Study (INCARD) | NCT01683903

CORolla™ TAA for Heart Failure and Preserved Ejection Fraction and Diastolic Dysfunction | NCT01956526

Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure (PH-HF) | NCT01545180

Bisoprolol Plasma Residual Concentrations in Chronic Heart Failure (PREVALENT) | NCT03644446

Articles citing this

(truncated to the top 100)

Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29

Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36

Decision making in advanced heart failure: a scientific statement from the American Heart Association. Circulation (2012) 3.61

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation (2014) 3.28

Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives. Dtsch Arztebl Int (2009) 2.72

Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol (2010) 2.68

Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med (2010) 2.21

A simple validated method for predicting the risk of hospitalization for worsening of heart failure in ambulatory patients: the Redin-SCORE. Eur J Heart Fail (2015) 2.01

Intravenous fluids in acute decompensated heart failure. JACC Heart Fail (2015) 2.01

De novo acute heart failure and acutely decompensated chronic heart failure. Dtsch Arztebl Int (2015) 1.93

Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation (2010) 1.73

Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure. Am J Med (2013) 1.61

A randomized trial of home telemonitoring in a typical elderly heart failure population in North West London: results of the Home-HF study. Eur J Heart Fail (2009) 1.55

Recent advances in cardiac resynchronization therapy: echocardiographic modalities, patient selection, optimization, non-responders--all you need to know for more efficient CRT. Int J Cardiovasc Imaging (2009) 1.51

What strategies are effective for exercise adherence in heart failure? A systematic review of controlled studies. Heart Fail Rev (2012) 1.49

Prognostic value of cardiopulmonary exercise testing in heart failure with preserved ejection fraction. The Henry Ford HospITal CardioPulmonary EXercise Testing (FIT-CPX) project. Am Heart J (2016) 1.47

Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace (2010) 1.47

Cardiac remodeling at the population level--risk factors, screening, and outcomes. Nat Rev Cardiol (2011) 1.43

Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. J Am Coll Cardiol (2016) 1.40

Lung ultrasound: a new tool for the cardiologist. Cardiovasc Ultrasound (2011) 1.40

Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol (2010) 1.39

Automatic identification of heart failure diagnostic criteria, using text analysis of clinical notes from electronic health records. Int J Med Inform (2013) 1.39

Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail (2012) 1.35

Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the korean heart failure registry. Korean Circ J (2011) 1.34

The potential harm of oxygen therapy in medical emergencies. Crit Care (2013) 1.28

Sympatho-renal axis in chronic disease. Clin Res Cardiol (2011) 1.26

The paradox of low BNP levels in obesity. Heart Fail Rev (2012) 1.23

A Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart Failure. Cardiorenal Med (2013) 1.22

Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail (2011) 1.20

Mitral valve surgery for mitral regurgitation caused by Libman-Sacks endocarditis: a report of four cases and a systematic review of the literature. J Cardiothorac Surg (2010) 1.18

Three gram sodium intake is associated with longer event-free survival only in patients with advanced heart failure. J Card Fail (2011) 1.17

Home monitoring for heart failure management. J Am Coll Cardiol (2012) 1.17

Shock or no shock - a question of philosophy or should intraoperative implantable cardioverter defibrillator testing be recommended? Interact Cardiovasc Thorac Surg (2012) 1.16

S3 guidelines for intensive care in cardiac surgery patients: hemodynamic monitoring and cardiocirculary system. Ger Med Sci (2010) 1.14

The early origins of chronic heart failure: impaired placental growth and initiation of insulin resistance in childhood. Eur J Heart Fail (2010) 1.13

Natriuretic peptides in the diagnosis and management of chronic heart failure. Heart Fail Clin (2009) 1.12

Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis. PLoS One (2014) 1.11

Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care (2010) 1.10

Effects of exercise training on heart rate variability in Chagas heart disease. Arq Bras Cardiol (2014) 1.08

High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia (2012) 1.08

Physical comorbidity and its relevance on mortality in schizophrenia: a naturalistic 12-year follow-up in general hospital admissions. Eur Arch Psychiatry Clin Neurosci (2013) 1.07

The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis (2013) 1.06

Natural history and outcome of hepatic vascular malformations in a large cohort of patients with hereditary hemorrhagic teleangiectasia. Dig Dis Sci (2011) 1.06

Biomarkers: optimizing treatment guidance in heart failure. Clin Res Cardiol (2011) 1.05

Prevalence of heart failure and atrial fibrillation in minority ethnic subjects: the Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). PLoS One (2011) 1.05

High intake of saturated fat, but not polyunsaturated fat, improves survival in heart failure despite persistent mitochondrial defects. Cardiovasc Res (2011) 1.05

Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics. Heart Fail Rev (2010) 1.05

Coronary artery disease in Africa and the Middle East. Ther Clin Risk Manag (2012) 1.05

In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure: the Italian RED Study. Crit Care (2010) 1.04

Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. J Am Coll Cardiol (2012) 1.02

A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol (2011) 1.02

Performance of claims-based algorithms for identifying heart failure and cardiomyopathy among patients diagnosed with breast cancer. Med Care (2014) 1.01

Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol (2012) 1.01

Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure. Eur J Heart Fail (2012) 1.01

Dietary fat and heart failure: moving from lipotoxicity to lipoprotection. Circ Res (2012) 1.00

The cardiorenal syndrome: a review. Int J Nephrol (2010) 1.00

Arterial hyperoxia and mortality in critically ill patients: a systematic review and meta-analysis. Crit Care (2014) 1.00

Heart failure and the risk of stroke: the Rotterdam Study. Eur J Epidemiol (2010) 1.00

Active tissue factor and activated factor XI in circulating blood of patients with systolic heart failure due to ischemic cardiomyopathy. Pol Arch Med Wewn (2010) 0.99

Elimination of phrenic nerve stimulation occurring during CRT: follow-up in patients implanted with a novel quadripolar pacing lead. J Interv Card Electrophysiol (2011) 0.98

Effects of Combined Early In-Patient Cardiac Rehabilitation and Structured Home-based Program on Function among Patients with Congestive Heart Failure: A Randomized Controlled Trial. Heart Views (2011) 0.97

Echocardiography, dyssynchrony, and the response to cardiac resynchronization therapy. Eur Heart J (2010) 0.97

The effect of a clinical pharmacist discharge service on medication discrepancies in patients with heart failure. Pharm World Sci (2010) 0.97

A feasibility study for the provision of electronic healthcare tools and services in areas of Greece, Cyprus and Italy. Biomed Eng Online (2011) 0.97

Implementation of pharmacotherapy guidelines in heart failure: experience from the German Competence Network Heart Failure. Clin Res Cardiol (2011) 0.96

S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res (2010) 0.96

Palliative care and hospice in advanced heart failure. Prog Cardiovasc Dis (2011) 0.96

Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol (2015) 0.95

Atypical "mid-ventricular" Tako-tsubo cardiomyopathy in a patient suffering from posttraumatic stress disorder: A case report. Wien Klin Wochenschr (2011) 0.95

The role of chest ultrasonography in the management of respiratory diseases: document II. Multidiscip Respir Med (2013) 0.95

Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the heart failure in care homes (HFinCH) diagnostic accuracy study. PLoS One (2013) 0.95

Levosimendan: current data, clinical use and future development. Heart Lung Vessel (2013) 0.95

Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure. Eur J Heart Fail (2013) 0.95

Higher serum uric acid on admission is associated with higher short-term mortality and poorer long-term survival after myocardial infarction: retrospective prognostic study. Croat Med J (2009) 0.94

Parathyroid hormone accelerates decompensation following left ventricular hypertrophy. Exp Mol Med (2010) 0.94

NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study. Respir Res (2012) 0.94

Can NT-proBNP be used as a criterion for heart failure hospitalization in emergency room? J Res Med Sci (2011) 0.94

Heart failure with preserved ejection fraction. Glob Cardiol Sci Pract (2012) 0.94

Rationale, Design, Methodology and Hospital Characteristics of the First Gulf Acute Heart Failure Registry (Gulf CARE). Heart Views (2014) 0.93

Evaluation of an open access echocardiography service in the Netherlands: a mixed methods study of indications, outcomes, patient management and trends. BMC Health Serv Res (2010) 0.93

Anticoagulation in heart failure: current status and future direction. Heart Fail Rev (2013) 0.93

Managing acute pulmonary oedema. Aust Prescr (2017) 0.93

The REFER (REFer for EchocaRdiogram) protocol: a prospective validation of a clinical decision rule, NT-proBNP, or their combination, in the diagnosis of heart failure in primary care. Rationale and design. BMC Cardiovasc Disord (2012) 0.93

I -123 metaiodobenzylguanidine imaging for predicting ventricular arrhythmia in heart failure patients. J Biomed Res (2013) 0.92

Optimizing fluid management in patients with acute decompensated heart failure (ADHF): the emerging role of combined measurement of body hydration status and brain natriuretic peptide (BNP) levels. Heart Fail Rev (2011) 0.92

Incremental Reduction in Risk of Death Associated With Use of Guideline-Recommended Therapies in Patients With Heart Failure: A Nested Case-Control Analysis of IMPROVE HF. J Am Heart Assoc (2012) 0.92

Treatment options in end-stage heart failure: where to go from here? Neth Heart J (2012) 0.92

Campylobacter jejuni-associated perimyocarditis: two case reports and review of the literature. BMC Infect Dis (2016) 0.92

Adiponectin, diabetes and ischemic heart failure: a challenging relationship. Cardiovasc Diabetol (2012) 0.91

White blood cell subtypes after STEMI: temporal evolution, association with cardiovascular magnetic resonance--derived infarct size and impact on outcome. Inflammation (2011) 0.90

Coronary artery disease is under-diagnosed and under-treated in advanced lung disease. Am J Med (2012) 0.90

Relation of natriuretic peptide concentrations to central sleep apnea in patients with heart failure. Chest (2011) 0.90

Chronic heart failure in older adults. Med Clin North Am (2011) 0.90

A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials (2011) 0.90

A re-appraisal of volume status and renal function impairment in chronic heart failure: combined effects of pre-renal failure and venous congestion on renal function. Heart Fail Rev (2012) 0.90

Prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with newly diagnosed non-ischemic cardiomyopathy: cohort study. PLoS One (2013) 0.89

High levels of B-type natriuretic peptide predict weaning failure from mechanical ventilation in adult patients after cardiac surgery. Clinics (Sao Paulo) (2013) 0.89

Heart failure in East Asia. Curr Cardiol Rev (2013) 0.89

Position paper on the importance of psychosocial factors in cardiology: Update 2013. Ger Med Sci (2014) 0.89

Feasibility of evidence-based diagnosis and management of heart failure in older people in care: a pilot randomised controlled trial. BMC Geriatr (2012) 0.88

Articles by these authors

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72

Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95

Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J (2012) 18.18

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 17.34

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J (2012) 16.00

Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J (2009) 14.06

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J (2012) 13.74

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet (2005) 12.92

2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J (2012) 12.36

Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J (2008) 12.31

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88

Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77

Universal definition of myocardial infarction. Circulation (2007) 11.69

Guidelines on the management of valvular heart disease (version 2012). Eur Heart J (2012) 10.70

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail (2012) 10.38

2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 9.80

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J (2014) 9.73

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54

Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43

Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13

Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J (2008) 8.20

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (2015) 7.99

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86

Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55

Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J (2007) 7.34

2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. Europace (2012) 7.33

Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation (2002) 7.25

Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail (2008) 6.80

Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med (2012) 6.60

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 6.55

ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J (2010) 6.45

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet (2012) 6.42

Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J (2007) 6.34

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25

2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J (2013) 6.17

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet (2015) 6.13

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10